Clinical Research Directory

Inclusion Criteria: * Histologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (high-grade serous preferred). * Recurrent or refractory disease after at least 2 prior systemic treatment lines (including a platinum-based regimen unless contraindicated). * Measurable disease per RECIST v1.1. * Tumor expresses at least two of the following targets above protocol-defined threshold: MSLN, FRalpha (FOLR1), MUC16 (CA 125) (archival or fresh biopsy). * ECOG performance status 0-1. * Adequate organ function : ANC \>= 1.0 x 10\^9/L; platelets \>= 75 x 10\^9/L; hemoglobin \>= 8 g/dL; AST/ALT \<= 3 x ULN (\<= 5 x ULN with liver metastases); total bilirubin \<= 1.5 x ULN; creatinine clearance \>= 50 mL/min. * Negative pregnancy test for women of childbearing potential; agreement to use effective contraception through 12 months post-infusion (or per local gene-therapy guidance). * Able to comply with study procedures and follow-up schedule; written informed consent. Exclusion Criteria: * Prior gene-modified cellular therapy (e.g., CAR-T, CAR-NK) within 6 months (or any prior therapy directed to the same target, per protocol). * Active central nervous system (CNS) metastases or carcinomatous meningitis requiring therapy. * Uncontrolled infection, including active tuberculosis; or clinically significant, uncontrolled viral infection. * Known HIV infection with uncontrolled viremia; active hepatitis B or hepatitis C with detectable viral load (testing required at screening). * Clinically significant cardiovascular disease (e.g., recent myocardial infarction, uncontrolled arrhythmia, NYHA Class III/IV heart failure). * Active autoimmune disease requiring systemic immunosuppression within 30 days (physiologic steroid replacement allowed). * Concurrent anti-cancer therapy (chemotherapy, targeted therapy, radiotherapy) not permitted within a protocol-defined washout period. * Major surgery within 4 weeks prior to lymphodepletion (except minor procedures) * Pregnant or breastfeeding. * Any condition that, in the investigator's judgment, would increase risk (e.g., severe pulmonary disease) or interfere with study interpretation.